JP2020532957A5 - - Google Patents

Download PDF

Info

Publication number
JP2020532957A5
JP2020532957A5 JP2020507103A JP2020507103A JP2020532957A5 JP 2020532957 A5 JP2020532957 A5 JP 2020532957A5 JP 2020507103 A JP2020507103 A JP 2020507103A JP 2020507103 A JP2020507103 A JP 2020507103A JP 2020532957 A5 JP2020532957 A5 JP 2020532957A5
Authority
JP
Japan
Prior art keywords
cancer
cells
hla
ebv
epstein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020507103A
Other languages
English (en)
Japanese (ja)
Other versions
JP7693189B2 (ja
JP2020532957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2018/009225 external-priority patent/WO2019031939A2/ko
Publication of JP2020532957A publication Critical patent/JP2020532957A/ja
Publication of JP2020532957A5 publication Critical patent/JP2020532957A5/ja
Priority to JP2023093867A priority Critical patent/JP2023113855A/ja
Application granted granted Critical
Publication of JP7693189B2 publication Critical patent/JP7693189B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020507103A 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法 Active JP7693189B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023093867A JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170101800 2017-08-10
KR10-2017-0101800 2017-08-10
PCT/KR2018/009225 WO2019031939A2 (ko) 2017-08-10 2018-08-10 암 치료를 위한 t 세포의 활성화 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023093867A Division JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Publications (3)

Publication Number Publication Date
JP2020532957A JP2020532957A (ja) 2020-11-19
JP2020532957A5 true JP2020532957A5 (enExample) 2021-09-09
JP7693189B2 JP7693189B2 (ja) 2025-06-17

Family

ID=65271692

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020507093A Active JP7364237B2 (ja) 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法
JP2020507103A Active JP7693189B2 (ja) 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法
JP2023093867A Withdrawn JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020507093A Active JP7364237B2 (ja) 2017-08-10 2018-08-10 癌治療のためのｔ細胞の活性化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023093867A Withdrawn JP2023113855A (ja) 2017-08-10 2023-06-07 癌治療のためのｔ細胞の活性化方法

Country Status (7)

Country Link
US (3) US11918634B2 (enExample)
EP (2) EP3666888A4 (enExample)
JP (3) JP7364237B2 (enExample)
KR (5) KR102148866B1 (enExample)
CN (2) CN110997903B (enExample)
BR (1) BR112020002816A2 (enExample)
WO (2) WO2019031939A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020162696A1 (ko) * 2019-02-08 2020-08-13 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
WO2020170254A1 (en) * 2019-02-21 2020-08-27 Ramot At Tel-Aviv University Ltd. Treatment of diseases with multimeric peptides
KR102182555B1 (ko) * 2019-03-14 2020-11-24 한국과학기술연구원 T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
WO2021061736A1 (en) * 2019-09-23 2021-04-01 Dana-Farber Cancer Institute, Inc. Methods of high-throughput identification of t cell epitopes by capturing cytokines on the surface of antigen-presenting cells
KR20210102091A (ko) 2020-02-11 2021-08-19 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
CN116018158A (zh) * 2020-04-30 2023-04-25 转化基因组学研究所 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法
GB202010095D0 (en) * 2020-07-01 2020-08-12 Tcer Ab Immunotherapy
KR20220118225A (ko) 2021-02-18 2022-08-25 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
KR20220131170A (ko) 2021-03-19 2022-09-27 주식회사 리스큐어바이오사이언시스 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물
CN114230656B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与食道癌驱动基因突变相关的抗原肽组合及其应用
CN116731964A (zh) * 2022-05-26 2023-09-12 苏州尔生生物医药有限公司 用于预防或治疗癌症的特异性t细胞及其制备方法
WO2024151124A1 (ko) * 2023-01-12 2024-07-18 주식회사 이뮤노맥스 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법
WO2025240737A1 (en) * 2024-05-16 2025-11-20 Rutgers, The State University Of New Jersey Methods of producing memory t cells in vitro and their use in immunotherapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
AU2003228067B2 (en) 2002-04-22 2008-05-29 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
ES2390967T3 (es) * 2004-01-20 2012-11-20 Aichi Prefecture Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
US20090155275A1 (en) * 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
KR20110036618A (ko) 2008-07-16 2011-04-07 베일러 리서치 인스티튜트 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
KR20120059581A (ko) * 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
CN101643497A (zh) * 2009-09-15 2010-02-10 南京医科大学 Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US9402916B2 (en) * 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
JP6081483B2 (ja) 2011-12-12 2017-02-15 セル・メディカ・リミテッド Ｔ細胞を増殖させるプロセス
GB201312133D0 (en) 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
US10987412B2 (en) * 2014-09-17 2021-04-27 The John Hopkins University Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
CA2986235A1 (en) * 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
WO2016203577A1 (ja) 2015-06-17 2016-12-22 株式会社医学生物学研究所 細胞傷害性ｔ細胞エピトープペプチド及びその用途
AU2016339924B2 (en) * 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
CA3003251A1 (en) * 2015-10-12 2017-04-20 Nantomics, Llc Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
KR102883915B1 (ko) * 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
AU2017271128A1 (en) * 2016-05-25 2019-01-03 The Council Of The Queensland Institute Of Medical Research Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
SG11201900132QA (en) * 2016-07-20 2019-02-27 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy

Similar Documents

Publication Publication Date Title
JP2020532956A5 (enExample)
AU2023233209B2 (en) Methods of preparing anti-human papillomavirus antigen T cells
Tarannum et al. Cytokine-induced memory-like natural killer cells for cancer immunotherapy
JP2022066355A (ja) 免疫療法向けのｔ細胞組成物
JP7693189B2 (ja) 癌治療のためのｔ細胞の活性化方法
JP6686008B2 (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
JP2017535253A (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
CN107630006A (zh) 一种制备tcr与hla双基因敲除的t细胞的方法
JP2018522072A5 (enExample)
JP2022002511A (ja) 病原体からの免疫原性抗原同定および臨床的有効性との相関
JP2019507608A5 (enExample)
JP6697076B2 (ja) ウイルス抗原特異的ｔ細胞の濃縮および拡大方法
Wagstaffe et al. Vaccinating for natural killer cell effector functions
DE602005022728D1 (de) Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
Goodier et al. Regulation of the human NK cell compartment by pathogens and vaccines
Lam et al. Highlight of 2023: Unlocking the therapeutic potential of natural killer cells—advances in adaptive functions, cellular engineering and immunotherapy.
CN106279392A (zh) 肿瘤相关抗原XAGE‑1b短肽及其应用
JP2014516538A5 (enExample)
PH12018501723A1 (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
ATE351904T1 (de) Einem peptid aus antigen muc-1 entsprechende dns zur auslösung einer immunreaktion gegen tumorzellen
JP7096397B2 (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
Chan et al. IL-10: expanding the immune oncology horizon
Shao et al. Engineered cells for costimulatory enhancement combined with IL-21 enhance the generation of PD-1-disrupted CTLs for adoptive immunotherapy
JP4111394B2 (ja) 改変標的化ｔ細胞の製造方法及び医薬